The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Mehnaj Ahmed
No Relationships to Disclose
 
Ashley Roush
Employment - Tennessee Oncology
 
Rohan Parikh
No Relationships to Disclose
 
Abigail Hitchens
No Relationships to Disclose
 
Sherry Shen
Honoraria - MJH Life Sciences
Research Funding - Merck (Inst); Sermonix Pharmaceuticals (Inst)
 
Anton Safonov
No Relationships to Disclose
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Nancy Walker Peacock
No Relationships to Disclose
 
Yanjun Ma
No Relationships to Disclose
 
Elizabeth Chertow Santarsiero
No Relationships to Disclose
 
Vaidyanathan Ganapathy
No Relationships to Disclose
 
Rohan M. Shah
Employment - Novartis
Travel, Accommodations, Expenses - Novartis
 
Adaeze Q. Amefule
Employment - Novartis
 
Agnes Lteif
No Relationships to Disclose
 
L. Johnetta Blakely
Employment - Tennessee Oncology
Leadership - HCA Healthcare
Honoraria - Novartis
Consulting or Advisory Role - GRAIL
Research Funding - Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck (Inst); Novartis (Inst)